A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats

Mingming Su; Yunping Qiu; Wei Jia

doi:10.1007/BF02850079

A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats

Mingming Su, Yunping Qiu, Wei Jia

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The inhibitory effects of gallium ethylenediamine-N,N,N′,N′- tetrakismethylene phosphonate [Ga(III)-EDTMP] was studied on a malignant tumor and metastatic bone lesion model induced with Walker carcinosarcoma 256 (WCS 256) in Wistar rats weighing 120 to 135 g. A water-soluble chelate, Ga(III)-EDTMP, was prepared for injection in a tumor-bearing model. Radiographic analysis at 14 days indicated that the bone invasion and osteolysis were markedly reduced in animals treated with Ga(III)-EDTMP. The calculated tumor inhibitory rates were 33.16±0.38% at a dosage of 5 mg/kg and 47.75±0.74% at 10 mg/kg. Biochemical markers such as serum calcium decreased by 23% (P<.05) and by 31% (P<.01) at dosages of 5 mg/kg and 10 mg/kg, respectively, whereas serum alkaline phosphatase (ALPase) activity decreased by 47% (P<.01) and 69% (P<.01) at the 2 dosages.

Original language	English (US)
Pages (from-to)	297-306
Number of pages	10
Journal	Advances in Therapy
Volume	22
Issue number	4
DOIs	https://doi.org/10.1007/BF02850079
State	Published - Jul 2005
Externally published	Yes

Keywords

Bone metastasis
Ga(III)-EDTMP
Gallium ethylenediaminetetramethylene phosphonate
Inhibitory rate
Osteolysis

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/BF02850079

Cite this

@article{a572133a048643ada83f13f419193e87,

title = "A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats",

abstract = "The inhibitory effects of gallium ethylenediamine-N,N,N′,N′- tetrakismethylene phosphonate [Ga(III)-EDTMP] was studied on a malignant tumor and metastatic bone lesion model induced with Walker carcinosarcoma 256 (WCS 256) in Wistar rats weighing 120 to 135 g. A water-soluble chelate, Ga(III)-EDTMP, was prepared for injection in a tumor-bearing model. Radiographic analysis at 14 days indicated that the bone invasion and osteolysis were markedly reduced in animals treated with Ga(III)-EDTMP. The calculated tumor inhibitory rates were 33.16±0.38% at a dosage of 5 mg/kg and 47.75±0.74% at 10 mg/kg. Biochemical markers such as serum calcium decreased by 23% (P<.05) and by 31% (P<.01) at dosages of 5 mg/kg and 10 mg/kg, respectively, whereas serum alkaline phosphatase (ALPase) activity decreased by 47% (P<.01) and 69% (P<.01) at the 2 dosages.",

keywords = "Bone metastasis, Ga(III)-EDTMP, Gallium ethylenediaminetetramethylene phosphonate, Inhibitory rate, Osteolysis",

author = "Mingming Su and Yunping Qiu and Wei Jia",

year = "2005",

month = jul,

doi = "10.1007/BF02850079",

language = "English (US)",

volume = "22",

pages = "297--306",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Health Communications Inc.",

number = "4",

}

TY - JOUR

T1 - A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats

AU - Su, Mingming

AU - Qiu, Yunping

AU - Jia, Wei

PY - 2005/7

Y1 - 2005/7

N2 - The inhibitory effects of gallium ethylenediamine-N,N,N′,N′- tetrakismethylene phosphonate [Ga(III)-EDTMP] was studied on a malignant tumor and metastatic bone lesion model induced with Walker carcinosarcoma 256 (WCS 256) in Wistar rats weighing 120 to 135 g. A water-soluble chelate, Ga(III)-EDTMP, was prepared for injection in a tumor-bearing model. Radiographic analysis at 14 days indicated that the bone invasion and osteolysis were markedly reduced in animals treated with Ga(III)-EDTMP. The calculated tumor inhibitory rates were 33.16±0.38% at a dosage of 5 mg/kg and 47.75±0.74% at 10 mg/kg. Biochemical markers such as serum calcium decreased by 23% (P<.05) and by 31% (P<.01) at dosages of 5 mg/kg and 10 mg/kg, respectively, whereas serum alkaline phosphatase (ALPase) activity decreased by 47% (P<.01) and 69% (P<.01) at the 2 dosages.

AB - The inhibitory effects of gallium ethylenediamine-N,N,N′,N′- tetrakismethylene phosphonate [Ga(III)-EDTMP] was studied on a malignant tumor and metastatic bone lesion model induced with Walker carcinosarcoma 256 (WCS 256) in Wistar rats weighing 120 to 135 g. A water-soluble chelate, Ga(III)-EDTMP, was prepared for injection in a tumor-bearing model. Radiographic analysis at 14 days indicated that the bone invasion and osteolysis were markedly reduced in animals treated with Ga(III)-EDTMP. The calculated tumor inhibitory rates were 33.16±0.38% at a dosage of 5 mg/kg and 47.75±0.74% at 10 mg/kg. Biochemical markers such as serum calcium decreased by 23% (P<.05) and by 31% (P<.01) at dosages of 5 mg/kg and 10 mg/kg, respectively, whereas serum alkaline phosphatase (ALPase) activity decreased by 47% (P<.01) and 69% (P<.01) at the 2 dosages.

KW - Bone metastasis

KW - Ga(III)-EDTMP

KW - Gallium ethylenediaminetetramethylene phosphonate

KW - Inhibitory rate

KW - Osteolysis

UR - http://www.scopus.com/inward/record.url?scp=29344466927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344466927&partnerID=8YFLogxK

U2 - 10.1007/BF02850079

DO - 10.1007/BF02850079

M3 - Article

C2 - 16418139

AN - SCOPUS:29344466927

SN - 0741-238X

VL - 22

SP - 297

EP - 306

JO - Advances in Therapy

JF - Advances in Therapy

IS - 4

ER -

A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this